PURPOSE: In Brazil, patients with gastric cancer have not been systematically followed-up and evaluated, thus data regarding patterns of care and outcomes are scarce or missing. The objective of this study was to evaluate patterns of care of advanced gastric cancer in standard practice in Brazil. METHODS: This was an observational, multicenter, retrospective study, which included patients with metastatic and/or unresectable gastric cancer (MGC) who underwent at least one line of treatment. RESULTS: We analyzed data on 155 patients diagnosed with MGC, most are men (57.4%), with mean age of 61.9 years at diagnosis, with 99 (63.9%) from the public healthcare system and 56 (36.1%) from the private setting. Platinum- and/or fluoropyrimidine-containing regimens prevailed as first-line therapy, while irinotecan was the most used regimen in the second and in the third lines. More than 40% of patients underwent only one line of systemic therapy, of which around 40% either died during the treatment or went on to best supportive care (BSC) only. The remaining patients received further treatment lines. A fifth of the patients in the study died within two months after discontinuation of the first-line treatment. Adverse events, use of concomitant medications, support procedures, outpatient visits, and hospitalizations were reported for most patients, especially in the first and second lines of treatment and during exclusive BSC. CONCLUSIONS: Survival during or after the first-line chemotherapy remains poor among patients with MGC. Adverse events and health resource use were common in the first and second lines of treatment and in exclusive BSC. These results suggest that there is space for improvement in the treatment of MGC in Brazil.
PURPOSE: In Brazil, patients with gastric cancer have not been systematically followed-up and evaluated, thus data regarding patterns of care and outcomes are scarce or missing. The objective of this study was to evaluate patterns of care of advanced gastric cancer in standard practice in Brazil. METHODS: This was an observational, multicenter, retrospective study, which included patients with metastatic and/or unresectable gastric cancer (MGC) who underwent at least one line of treatment. RESULTS: We analyzed data on 155 patients diagnosed with MGC, most are men (57.4%), with mean age of 61.9 years at diagnosis, with 99 (63.9%) from the public healthcare system and 56 (36.1%) from the private setting. Platinum- and/or fluoropyrimidine-containing regimens prevailed as first-line therapy, while irinotecan was the most used regimen in the second and in the third lines. More than 40% of patients underwent only one line of systemic therapy, of which around 40% either died during the treatment or went on to best supportive care (BSC) only. The remaining patients received further treatment lines. A fifth of the patients in the study died within two months after discontinuation of the first-line treatment. Adverse events, use of concomitant medications, support procedures, outpatient visits, and hospitalizations were reported for most patients, especially in the first and second lines of treatment and during exclusive BSC. CONCLUSIONS: Survival during or after the first-line chemotherapy remains poor among patients with MGC. Adverse events and health resource use were common in the first and second lines of treatment and in exclusive BSC. These results suggest that there is space for improvement in the treatment of MGC in Brazil.
Authors: Peter C Thuss-Patience; Albrecht Kretzschmar; Dmitry Bichev; Tillman Deist; Axel Hinke; Kirstin Breithaupt; Yasemin Dogan; Bernhard Gebauer; Guido Schumacher; Peter Reichardt Journal: Eur J Cancer Date: 2011-10 Impact factor: 9.162
Authors: Anna Dorothea Wagner; Susanne Unverzagt; Wilfried Grothe; Gerhard Kleber; Axel Grothey; Johannes Haerting; Wolfgang E Fleig Journal: Cochrane Database Syst Rev Date: 2010-03-17
Authors: Jung Hun Kang; Soon Il Lee; Do Hyoung Lim; Keon-Woo Park; Sung Yong Oh; Hyuk-Chan Kwon; In Gyu Hwang; Sang-Cheol Lee; Eunmi Nam; Dong Bok Shin; Jeeyun Lee; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang; Se Hoon Park Journal: J Clin Oncol Date: 2012-03-12 Impact factor: 44.544
Authors: Bruno Zilberstein; Carlos Malheiros; Laercio Gomes Lourenço; Paulo Kassab; Carlos Eduardo Jacob; Antonio Carlos Weston; Cláudio José Caldas Bresciani; Osvaldo Castro; Joaquim Gama-Rodrigues; Aldenis Albaneze Borin; Carlos Buchpiegel; André Montagnini; Celso Vieira Leite; Claudio Roberto Deutsch; Cleber Dario Pinto Kruel; Donato Mucerino; Durval Wohnrath; Elias Ilias; Fátima Mrué; Fauze Maluf-Filho; Felipe Rocha; Fernando de Souza; Flávio Saavedra Tomasich; Geraldo Ishak; Gustavo Laporte; Hamilton Petry de Souza; Ivan Cecconello; Jaime Eisig; Jorge Ohana; Jorge Sabagga; José Carlos del Grande; José Paulo de Jesus; José Soares; Luis Antonio Negrão Dias; Luiz Fernando Moreira; Mariangela Correa; Marineide Carvalho; Nelson Adami Andreollo; Nelson Dell Áquila; Nicolau Gregori Czeczko; Nicolau Kruel; Nora Manoukian Forones; Orlando Milhomem da Motta; Osvaldo Malafaia; Paulo Assumpção; Paulo Leonardi; Paulo Sakai; Paulo Roberto Savassi Rocha; Ramiro Colleoni; Roberto Gurgel; Roberto Pelegrini Coral; Sidney Chalub; Ulisses Ribeiro- Junior; Venancio Avancini Ferreira Alves; Vinicius de Lima Vasquez; Vladimir Nadalin Journal: Arq Bras Cir Dig Date: 2013 Jan-Mar
Authors: Sudeep Karve; Maria Lorenzo; Astra M Liepa; Lisa M Hess; James A Kaye; Brian Calingaert Journal: J Gastric Cancer Date: 2015-06-30 Impact factor: 3.720